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ABSTRACT
Human Papilloma Virus (HPV) is one of the most common sexually transmitted
infections. There are over 150 different genotypes of HPV. Some cause benign warts,
while others cause several types of cancer. Subunit vaccines comprised of the capsid
protein from an increasing number of HPV genotypes have been developed; however,
the vaccines are prophylactic and are documented to protect against only 9 of the HPV
genotypes. Importantly, there are also significant limitations in the clinical detection of
HPV.
Current clinical tests can only specifically identify HPV16 and HPV18. One of the
test also detects 12 of the other high-oncogenic risk genotypes, but these are simply
designated as “other”, leaving majority of the HPV genotypes undiagnosed. Thus, there
is a gap in clinical diagnostic assays available and a resulting gap in knowledge about
the prevalence of many of the high-oncogenic risk HPV genotypes in the population and
the cancer risk associated with these undiagnosed HPV genotypes. As such, the
objective of this project was to establish the assays necessary to enable the clinical
detection of more of the known high oncogenic-risk HPV genotypes and to determine
the prevalence and cancer risk associated with these genotypes. Aim 1 was to establish
and validate genotype-specific TaqMan RTqPCR assays to screen clinical samples for
additional HPV genotypes. Aim 2 was to utilize these HPV genotype-specific assays to
assess the prevalence of the different HPV genotypes and associated pathology in
high-risk patients at the Edward Hines, Jr. Veterans Administration Hospital.
ix

Importantly, these efforts will also establish a cohort in which HPV genotype
cancer-risk can be followed longitudinally with data and samples obtained
approximately every 6 -12 months. The goal of these efforts is to demonstrate the value
of enhanced clinical diagnosis and enable the research necessary to define the
prevalence, oncogenic risk, and possibly vaccine sensitivity of other HPV genotypes of
concern.
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CHAPTER ONE
INTRODUCTION
HPV Infection Overview
Human Papilloma Virus (HPV) is a small non-enveloped DNA virus which
belongs to the family papillomaviridae (37). It is one of the most common sexually
transmitted infections in the United States (1). The spread of HPV is through sexual
contact, from mother to newborn baby and sharing of personal hygiene products (2).
HPV infects the undifferentiated cells in the lower layer of the squamous epithelium
when they are exposed via cuts or abrasions (3). There are over 150 different HPV
genotypes (8), some of which are oncogenic and capable of causing several types of
cancer and others which are non-oncogenic and cause benign warts (9). Each HPV
genotype shows a preferred epithelial site of infection dictated in part by the
environment best suited for that genotype to replicate and maintain infectious virion
production (25). Approximately half of the known HPV genotypes are capable of
infecting the genital tract (18). While the majority of those who become infected clear
the virus via cell-mediated immunity (39) without ever developing clinically recognized
manifestations (5), in others, HPV can lead to persistent infection causing warts and/or
the development of precancerous lesions which can further transform into cancer (6, 7).
The rate of HPV clearance is much higher in those who become infected with nononcogenic HPV genotypes than in those who become infected with oncogenic HPV
infections (40).
1
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Benign HPV warts typically occurs within 1 to 3 months of exposure to the nononcogenic HPV genotypes (121). They can vary from small red bumps to very large
growths that can be extremely painful (Fig. 1). Genital warts can also cause severe pain
during intercourse. In pregnant women, the warts can enlarge and cause difficulty
during urination as well as inhibit the stretching of the vaginal tissues during childbirth
(141). HPV related cancer occurs after several years of persistent infection with the
oncogenic HPV genotypes and do not usually present symptoms until the final stages of
the cancer (122).

Figure 1. Benign Warts Caused by HPV Infection. HPV infection related warts can
develop in and around the genitals, mouth and anus.

Public Health Impact of HPV
The most common low-oncogenic risk HPV genotypes, HPV6 and 11, are
associated with genital warts and are also the predominant cause of Recurrent
Respiratory Papillomatosis (RRP), a condition characterized by development of multiple
papillomas in the larynx of infants and younger children (34). HPV infections are most
common in young women often occurring shortly after the onset of sexual activity (72)
with peak prevalence occurring around the age of 20-25 years (41). According to the
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National Health and Nutrition Examination Survey (NHANES), the prevalence of genital
infection with HPV was 42.5% among the total population of US adults aged 18–59
years during 2013–2014 (Fig. 2). While HPV infection is present in all populations, the
highest prevalence can be seen in non-Hispanic blacks (4).

Figure 2. Prevalence of Genital HPV Among Adults aged 18-59. Illustration of genital
HPV prevalence among adult aged 18-59 by race, sex and Hispanic origin. Total
population infected with HPV is at 42.5%, however prevalence of infection is equal in
both men and women. Also, while HPV infection is present in all populations, the highest
prevalence can be seen in non-Hispanic blacks. From (4).

The different HPV genotypes are divided into 5 genera based on their DNA
sequence homology. The known high oncogenic-risk HPV subtypes cluster in the alpha
genus (Fig. 3, red lines). Likewise, the two most common low oncogenic-risk HPV
genotypes that cause over 90% of genital warts are also found in the alpha genus (Fig.
3, purple lines). In contrast, the HPV genotypes that cause common skin warts are
found across multiple genera (Fig. 3, blue lines)(69).

4

Figure 3. HPV Genotypes Mapped by Genera. Reproduced from (70).

On a global scale, HPV infection accounts for more than 50% of infection-linked
cancers in women and approximately 5% in men (17), with prevalence being highest in
third world countries such as those in Sub-Saharan Africa, Latin American and Eastern
Europe (32) (Fig. 4).
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Figure 4. Global Incidence and Mortality Rates of HPV Infection Related Cervical
Cancer. (A) Incidence and mortality per 100,000 women is indicated. (B) Pie charts
indicate percentage of HPV cases in each region . From (154).

The two most prevalent high oncogenic risk HPV genotypes, HPV16 and HPV18
have been associated with several forms of cancer such as vaginal, oropharyngeal, and
penile cancer as well as other anogenital cancers including cervical cancer and anal
cancer (35, 72). Cervical cancer is one of the major types of cancer caused by HPV
(10), with HPV16 and HPV18 being responsible for approximately 70% of cervical
cancer cases in women worldwide (14, 71). Other high-oncogenic risk HPV genotypes
include HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 (8, 15, 16). Cervical cancer
is the second most common cancers that affect women worldwide (11) and HPV
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specifically accounts for ~530,000 cases of cervical cancer and ~270,000 deaths
annually (12).
There are 5 main stages of cervical cancer that allows physicians to determine
how far the disease has progressed (Table 1). Advanced cervical cancer eventually
leads to vaginal bleeding. The spread of the tumor to distant organs during the final
stages of cervical cancer causes pain, nausea and vomiting, fever, weakness,
incontinence, depression, wasting and eventually death (76).
Table 1. Stages of Cervical Cancer. Reproduced from (75).
Stages
0
I
II
III
IV

Characteristics
Carcinoma in situ. Abnormal cells present only in the innermost
lining of the cervix
Invasive carcinoma confined to the cervix with the presence of a
clinically visible lesion about 4cm in diameter
Spread of the cancer just beyond the uterus and into the vagina
without invading the parametrium
Spread of the cancer to the pelvic side wall and invading the ureter
resulting in non-functioning kidneys
Spread of the cancerous tumor beyond the pelvis and into the
bladder or the rectum as well as metastasis into distant organs

HPV also accounts for 90% of anal cancer worldwide and has a significantly
higher incidence rate in HIV infected men who have sex with men (MSM) (13,124,125).
The incidence rate of anal cancer has increased over the past several years in both
men and women (126); however, recent epidemiological studies indicate that black
MSM had higher reported cases of anal HPV infection, dysplasia and cancer in
comparison to their counterparts of other races (127). Several risk factors for developing
anal cancer include HPV infection, HIV infection, having multiple sexual partners,
repetitive anal intercourse, smoking and chronic immunosuppression (128). Screening
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measures such as anal Papanicolaou (Pap) smears of high-oncogenic risk groups have
been proposed to have significant benefits in early detection of anal cancer and
improvement in the overall life expectancy of infected individuals (129).
HPV Treatment and Prevention
Currently, there are no antiviral treatment available to clear HPV infection (2).
Once a cancerous HPV legion is identified, one treatment option is surgical removal of
the tumor using methods such as cryotherapy, cold knife cone biopsy, cold-coagulation
and a loop electrosurgical excision procedure (LEEP) (78). The treatment of more
advanced cancer cases involves concomitant chemoradiotherapy using a cis-platin
based regimen, which is a chemotherapy drug used to treat several different types of
cancer (77). Overall, the chances of cervical cancer survival are high when detected
early and treated with conization, radical hysterectomy and radiation therapy (79).
However, due to late screenings, cervical cancer is not detected early enough in most
women. Over 20% of cervical cancer cases are found in women over the age of 65
(168).
Over the years, subunit vaccines comprised of the self-assembling capsid
protein(s) (29) from an increasing number of HPV genotypes have been developed to
prevent HPV infection. These virus-like particles (VLPs) are produced using either the
L1 capsid protein alone or a combination of both structural proteins, L1 and L2 (Fig. 5).
(18).VLPs are not infectious because they lack the viral DNA. However, structurally from
the outside they closely resemble the natural virus and thus elicit an immune response
resulting in the production of antibodies against the viral capsid (19).
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Figure 5. HPV Vaccines. The bivalent vaccine (Cervarix) was developed in 2006. The
quadrivalent vaccine (Gardisil) targets HPV16 and 18, as well as two additional low
cancer risk HPV genotypes; HPV6 and11. The most recent nonavalent vaccine
(Gardisil-9) targets 7 of the high cancer risk HPV genotypes; HPV 16, 18, 31, 33, 45,
52 and 58, as well the two low cancer risk HPV genotypes; HPV6 and 11. Reproduced
from (143)

The HPV VLPs are produced via expression of the capsid protein(s) in yeast
cells (130). The L1 gene self-assembles into empty non-infectious capsid-like structures
that are immunogenetically similar to the authentic HPV virion (Fig. 6) (29). The HPV
vaccine is administered via intramuscular injection in a series of 2 doses for those
initiating vaccination between 9 to 14 years old and a series of 3 doses for those
initiating vaccination between 15 to 26 years old. The 3-dose series is also
recommended for adults initiating vaccinations at the ages of 27 to 45 years (82).
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Figure 6. Assembly of HPV L1 and L2 Proteins into Non-Infectious VLP.
Adapted from (81).

The HPV VLP vaccines have shown success in preventing HPV infections and
reducing cervical cancer (20). Results from one 2006 randomized control trial
experiment indicated a 100% VLP vaccine efficacy against cervical intraepithelial
neoplasia (CIN) lesions for 4.5 years (36). The VLP vaccines work by eliciting strong
serum titers of immunoglobulin G antibody (38). These antibodies then neutralize the
virus upon entry before it progresses to infect the basal epithelial cells (39). The HPV
vaccine only shows efficacy when given to HPV uninfected people (5), but not when
given to those who already are infected thus making it purely prophylactic (43). As such
the vaccines must be given early in life before people are exposed, which for many
occurs when they become sexually active (5, 22).
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While the vaccine can be prohibitively expensive for those without insurance
(21), more teenagers from families below the poverty level have received their first dose
of the HPV vaccine due to the federally funded Vaccines for Children program which
covers vaccines for uninsured or low-income teens (83). However, the HPV vaccination
rate is still higher in urban populations than in rural populations (Fig 7).

Figure 7. Estimated HPV Vaccine Coverage Among Adolescents aged 13-17 in
the US. From (84).

HPV Molecular Virology
HPV belongs to the family Papillomaviridae which are a family of non-enveloped
DNA viruses with icosahedral symmetry (23, 18). HPV consists of a small double
stranded circular DNA genome of about 8000 base pairs and approximately 8 open
reading frames (ORFs) (18) (Fig. 8) which express 8 proteins (Table 2). The genome is
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divided into 3 regions; the Locus Control Region (LCR), the early genes; E1 to E7 and
the late genes; L1 and L2 (30).

Figure 8. Illustration of HPV16 Molecular Genome. Reproduced from (12).

The LCR, also called the URR (Upstream Regulatory Region) is a non-coding
region which contains regulatory sequences responsive to cellular and virally-encoded
transcriptional regulators that control viral replication and transcription (33). Upon
infection of non-differentiated cells, cellular transcription factors such as AP1, SP1,
OCT1 and YY1 bind to the LCR to regulate expression of the early genes, E1, E2, and
E5, to maintain the HPV genome as low copy episomes (131, 132).
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Table 2. List of HPV Proteins and Their functions. Reproduced from (30)
HPV Proteins
E1
E2
E4
E5
E6
E7
L1
L2

Functions
Activates DNA helicase for viral genome replication
Initiates viral transcription and regulates replication
Essential for E2 function and facilitates maturation of viral particles
Viral growth stimulation and continuous proliferation of host cell
Viral oncoprotein that binds and degrades p53
Viral oncoprotein that binds and represses Rb family proteins
Major capsid protein
Minor capsid protein

The virally encoded E2, is a multifunctional protein, but was first recognized as a
transcription regulator. It binds the LCR to regulate viral transcription. Low levels of the
E2 protein activates transcription from the viral LCR whereas high levels repress
transcription, particularly of E6 and E7, serving as a negative feedback control system
(51). While it is not known how E2 represses expression of E6 and E7, one hypothesis
is simple steric interference with positive regulatory factors has been proposed (133,
134, 135).
In addition, E2 has a critical role in genome replication to stabilize the binding of
E1 to the viral origin of replication located in the LCR (50). The E1 protein is a helicase
and provides the DNA unwinding required for the initiation of viral replication (45, 85). It
binds independently, but the stability provided by E2 enhances genome replication.
E4 plays a major role in the amplification of the viral genome by inducing keratin
cytoskeletal disruption that causes the arrest in the G2 stage of the cell cycle in the
keratinocytes (30, 54). The E4 protein prevents the keratinocytes from undergoing
mitosis by sequestering the active cell cycle protein cyclin-dependent kinase 1
(Cdk1/cyclin B1) into the cytokeratin network and therefore prevents its accumulation in
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the nucleus where it is needed to initiate mitotic entry (142) (144). Without the initiation
of mitosis, the virus is able to utilize the host cell’s DNA replication machinery without
the competition it would normally encounter if the cell were to progress through the cell
cycle. In high-oncogenic risk HPV types such as HPV16, the G2 arrest function of the
E4 protein is shown to inhibit E6/E7 mediated cellular proliferation in the mid-epithelial
layers of the cell and thereby contributes to the timely onset of vegetative viral genome
amplification (86). E4 has also been shown to associate with and cause disruption to
the keratin intermediate filament network, weakening the integrity of the cellular
structure and promoting the release of progeny virions (87, 88).
The E5 genes have been shown to stimulate viral growth by interacting with the
host epidermal growth factor (EGF) receptor (55) and enhancing the growth factor
signaling pathways, allowing continuous proliferation of the host cell. HPV E5 protein
acts synergistically with EGF to enhance DNA synthesis in primary human keratinocytes
(98).
E6 and E7 are the primary viral oncogenes, with E6 targeting p53 tumor
suppressor and E7 targeting the Retinoblastoma (Rb) family of tumor suppressor
proteins (12, 56). The interaction of E6 with p53 and the E6- associated protein (E6-AP)
ubiquitin ligase causes the rapid degradation of p53 (Fig. 9) (57). The ubiquitin
mediated degradation of p53 prevents p53 transcriptional control of important cellular
functions such as activation of DNA repair, slowing of cell cycle progression and DNA
damage induced apoptosis thereby creating a transformative cellular environment (58)
(59). The interaction of E7 and Rb leads to the dissociation of the E2F-pRB complex
(27) that normally represses/controls E2F-mediated cell cycle progression from the G1
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to S phase (Fig. 9) (61, 62).This increase in the E2F activity promotes unregulated cell
proliferation (66). Importantly, it is thought that these two proteins promote HPV genome
replication, as they activate the expression of the host cell S phase DNA replication
proteins that are required for HPV replication, which depends on the host cell DNA
replication machinery.

Figure 9. Illustration of how HPV E6/E7 Affects Cellular Proliferation. Adapted
from (59).

Once the infected cells become terminally differentiated in the upper layers of the
epithelium, critical cellular transcriptional enhancers become expressed and activate the
promoters of the late genes L1 and L2. Because L1 and L2 provide the structural
components needed for the viral capsid, HPV only produces progeny virus in
differentiated epithelial cells; the cells found in the epidermis of the stratified epithelium
(44). The L1 gene forms the major HPV capsid which is composed of 72 pentamers
linked together via disulfide bonds (8, 103). The L1 protein forms the entire exterior
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surface of the mature HPV virion and mediates initial virion attachment to the host cell
(108). The ability of the L1 protein to spontaneously self-assemble into VLPs without the
help of chaperones made it a good target for the HPV vaccines (29, 109). The L2
protein which functions as the minor capsid protein colocalizes with the L1 protein, the
E2 protein and the viral genome to facilitate the encapsidation and assembly of
infectious virions (110). In the beginning stages of the HPV life cycle, the L2 protein
guides the genomic viral DNA as it traffics through the cell and makes its way into the
nucleus. In the late stages of the viral life cycle, the L2 protein plays a major role in
stabilizing the viral capsid by interacting with L1 (146). The L1 and L2 proteins function
together to facilitate the packaging and release of newly assembled HPV virions (89).
The HPV life cycle can be divided into 5 canonical stages, (1) attachment, (2)
entry, (3) genome replication, (4) particle assembly and (5) virion release (Fig. 10). HPV
infection begins when the virus first gains access to the basal epithelium through micro
abrasions of the epithelial tissue, and attaches to the epithelial cells located adjacent to
the basal membrane through the help of cell surface heparan sulfate, however the
primary viral receptor for HPV is still under debate (90, 91,145) (Fig. 10, #1) . After
attachment to the cell surface, HPV is internalized into the cell via clathrin-mediated or
caveolin-1 endocytosis (92) (93). Disassembly and release of the L2/genome complex
occurs in the endolysosomal pathway followed by trafficking of the L2/genome complex
to the transgolgi network, the Golgi and the ER before entering the nucleus via an
unknown mechanism, though it is speculated that this is dependent on nuclear
membrane breakdown during cellular division (Fig. 10, #2).
Once in the nucleus, viral replication begins with transcription of the viral genes.

16
Transcriptional regulation is linked to the differentiation state of the host cell and in the
initially infected undifferentiated cells, begins with expression of the early genes from
the LCR. E2 further enhances viral transcriptions and facilitates E1 helicase binding to
the viral origin of replication allowing for replication of the HPV episome by the host cell
machinery during cellular S-phase (Fig. 10 #3i). In these undifferentiated cells, the viral
genome is maintained at about 20-100 copy numbers (94). As the cell divides, infected
daughter cells move up from the basal layer towards terminal differentiation (99). This
differentiation triggers transcriptional upregulation of the E4 protein which inhibits the
G2 to M progression of the cell cycle allowing the virus to switch to a replication state,
called vegetative replication, in which there is much greater amplification of the viral
genome (95)(Fig. 10, #3iii). As the cells continue to differentiate, transcriptional
activation of the late genes occurs and the amplified viral genomes become packaged
into viral particles (Fig. 10, #4). It is thought that these progeny virions are released
passively as the terminally differentiated keratinocytes of the stratified epithelium die
(Fig. 10, #5).
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Figure 10. Illustration of the HPV Life Cycle. Adapted from (89).

HPV and Cancer
HPV exploits the host replication machinery to promote its own viral replication
and as a result, interferes with normal cell cycle control leading to abnormal cell growth
and creating an environment that promotes malignant transformation (113)(Fig. 11).
Transient infection produces some abnormal cell proliferation. If this involves 1/3 or less
of the thickness of the epithelium it is classified as cervical intraepithelial neoplasia
(CIN) grade 1 (CIN-1). However, as persistent infection is established, the increased
expression of the viral E6 and E7 oncogenes, which interact with cell cycle regulators
p53 and pRb, respectively, drive increased cellular proliferation and genetic instability.
Once this effects 1/3 - 2/3 of the epithelium, the pathological condition is classified as
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CIN-2 (28). The final stages of transformation typically include integration of the HPV
DNA into the host cell genome leading to disruption of the E2 gene which normally
controls the levels of the E6 and E7 genes (116). Loss of E2 therefore results in the
further over-expression of E6 and E7 oncogenes which drives the final stages of
transformation affecting more than 2/3 of the epithelium (CIN-3) leading to invasive
cancer (19).

Figure 11. Illustration of the Stages of HPV Related Cervical Intraepithelial
Neoplasia (CIN) Grades 1-3. Reproduced from (74).

Limitations in HPV Clinical Testing
Despite the devastating impact of HPV on public health and individual lives, there
are currently significant limitations in the clinical detection of HPV. Aside from the fact
that the available clinical tests are only FDA-approved for women (Table 3) (107) often
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resulting in men being undiagnosed, out of the 150 different HPV genotypes that exist,
the current clinical diagnoses for HPV can specifically identify only two of these
genotypes, HPV16 and 18. Some of the available tests detect a few additional
genotypes and one test (COBAS Roche 4800 HPV test) detects 14 of the other
common HPV genotypes; however, these additional genotypes are not individually
identified but are simply designated as “other”. This leaves the vast majority of HPV
genotypes as undiagnosed and the diagnosis of ‘other’ gives little to no clinical insight
regarding the patients’ risk of cancer development. Even though HPV16 and 18 are the
most common genotypes associated with HPV related cervical cancer and anal cancer,
the other high oncogenic-risk genotypes are often associated with other types of cancer,
including head and neck cancer as well as vaginal and penile cancer. Yet, the actual
prevalence and oncogenic risk is unknown as these genotypes are not being monitored
sufficiently. Therefore, there is a gap in clinical diagnostic assays available and a
corresponding gap in knowledge about the prevalence of the other high-oncogenic risk
HPV genotypes in the population, and thus the true cancer-risk associated with these
undiagnosed HPV genotypes.
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Table 3. List of HPV FDA Approved Tests. From (107).
Test

Digene
Hybrid
Capture 2
Cervista™
HPV HR
and
Genfind™
Cervista™
HPV 16/18
COBAS
Roche
4800

Year
FDAApproved

Test Type

2003

nucleic acid
hybridization
(chemiluminescence)

2009

Invader Reporter
Assay
(hybridization/FRET)

2009

Invader Reporter
Assay
(hybridization/FRET)

2011

PCR

2011

Nucleic Acid
Amplification Test

Aptima

HPV Genotypes
Detected

Non-specifically
detects: 13 highoncogenic risk
genotypes
Non-specifically
detects: 14 highoncogenic risk
genotypes
Specifically detects:
HPV16 and HPV18
Specifically detects:
HPV16, HPV18
Non-specifically
detects: 12 “other”
Non-specifically
detects: 14 highoncogenic risk
genotypes

Target

Full
genome

E6/E7

E6/E7

L1

E6/E7
RNA

Summary and Significance of Thesis
HPV infection is the most prevalent sexually transmitted disease in the United
States (1) responsible for ~530,000 cancer cases and an approximate ~270,000 deaths
annually worldwide (12), yet diagnosis and consequently HPV research has been
limited by clinical tests that fail to specifically detect all the different high oncogenic-risk
HPV genotypes. Therefore, the goal of this project was to establish HPV genotypespecific assays to distinguish 13 of the known high oncogenic-risk HPV genotypes to
enable screening of clinical samples and facilitate the research needed to determine the
prevalence and true oncogenic risk of the non-HPV16/18 genotypes. We hypothesize
that being able to detect these individual HPV genotypes will reveal that some of them
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are more prevalent than assumed and perhaps show higher rates of association with
development of pre-cancerous/cancerous lesions (i.e. maybe they are of higher risk that
realized). We hope that these assays might reveal the value of HPV genotyping and
provide a basis for enhancing knowledge and perhaps future effective HPV testing.
As such, the long-term objective of these efforts is to establish a cohort of HPV
positive patients that can be followed longitudinally to assess not only prevalence of the
different HPV genotypes, but correlate HPV genotype with cancer risk/progression. The
objective of this one year thesis was to establish the RTqPCR assays necessary to
allow the clinical detection of 13 of the known high-oncogenic-risk HPV genotypes and
then to use those assays to do a cross-sectional screen of patients to determine the
prevalence of the various HPV genotypes in the samples collected to date. These goals
were to be achieved though the following specific aims:
Aim 1 - Establish RTqPCR assays to detect 13 of the known high
oncogenic-risk HPV genotypes.
Aim 2 - Collect samples from high HPV risk patients and assess the
relative prevalence of the different HPV genotypes
Chapter 2 describes the important details of the RTqPCR assays we have
established, while Chapter 3 describes the work completed. This includes the results
obtained while validating the initial 14 TaqMan RTqPCR assays planned as well as the
development of a pan genotypic HPV SYBR Green RTqPCR assay that became
necessary when we realized that the Edward Hines, Jr. Veterans Affairs (VA) Hospital
was not ordering the most complete test available that provides results for HPV16,
HPV18, and “other” (COBAS Roche 4800), which was needed to tell us which samples
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were HPV+ and should be screened for specific HPV genotypes. In both cases, we were
able to establish assays that performed well detecting purified plasmid DNAs with a high
degree of sensitivity and specificity, however we still have technical issues to overcome
as we cannot detect HPV with the same degree of sensitivity in clinical samples. In
addition, in Chapter 3, we detail the collection, processing and banking of clinical
samples from 111 participants prior to the CoVID19 pandemic shut down. Finally,
Chapter 4 discusses immediate plans for optimizing both the pan-genotypic SYBR
Green assay and the genotype-specific TaqMan assays as well as future plans for the
project as a whole.

CHAPTER TWO
MATERIALS AND METHODS
Plasmids
Plasmids containing 12 of the suspected high oncogenic risk HPV genotypes
(HPV16, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66) as well as one low oncogenic
risk HPV genotype (HPV 6B) were obtained from the Karolinska Institute (Table 4). A
Plasmid containing the high oncogenic risk HPV18 was obtained from ATCC (Table 4).
Plasmids were amplified in E.coli and multiple diagnostic digests were performed to
confirm plasmid identity (data not shown).
Table 4. List of HPV Plasmids
Plasmid Name
pBR322_HPV6B

[ug/ul]
0.192

260/280
1.9

pUC19_HPV31
pBRder_HPV33
pBR_HPV35
pSP65_HPV39
pGEM_HPV45
pUC13_HPV51
pUC19_HPV52
pT713_HPV56
pLINK322_HPV58
pUC9_HPV59
pBR322_HPV66
pBR322_HPV16
pBR322_HPV18

0.317
0.472
0.426
0.380
0.632
0.427
0.617
0.076
0.195
0.231
0.148
0.161
0.194

1.9
1.5
1.5
1.9
1.8
1.9
1.9
1.9
1.9
1.9
1.9
1.9
1.9
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Reference
153
155
156
157
158
159
160
161
162
163
164
165
166
ATCC cat# 45152D
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HPV Genotype Specific TaqMan Real Time Quantitative PCR (RTqPCR)
A universal forward primer (PTf) was used and paired with 4 distinct reverse
primers (PTrGrp1, PTrGrp2, PTrGrp3, PTrGrp4) that were able to recognize and amplify
3-4 HPV genotypes when paired with the universal forward primer. The 3-4 HPV
genotypes amplified by these 4 primer pairs are then individually detected using probes
that specifically recognize a single HPV genotype (Table 5). The idea behind this
strategy was to eventually allow for multiplexing. Hence each probe in each primer
group was tagged with a different fluorophore (Table 5). For all assays, Prime Time
Gene Expression master mix (IDT, cat # 1055772) was utilized. The cycling conditions
were 3 min at 95°C and a two-step cycle of 95°C for 15 s, 45°C for 30 s and 60°C for 60
s for a total of 45 cycles. The HPV plasmids in Table 4 were used to create standard
curves to provide a means of determining absolute HPV copies per reaction.
Pan-Genotypic SYBR Green RTqPCR
In order to detect all HPV genotypes and determine which clinical samples
warrant more analysis, we developed a pan-genotypic SYBR Green RTqPCR assay.
For this we utilized the same universal TaqMan HPV forward primer and designed a
universal pan-genotypic reverse primer (Pan-GTr) (Table 5). Bio-Rad iTAQ Universal
SYBR Green master mix was utilized with the following amplification conditions: 3 min
at 95°C and a two-step cycle of 95°C for 15 s, 45°C for 30 s and 60°C for 60 s for a total
of 45 cycles.
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Table 5. HPV Primers and Probes. ‘I’ indicates inosine, a purine nucleotide. (LNA)
residues are indicated by a “+” before the nucleotide. Primers and probes were ordered
from Integrated DNA Technologies.
Name
Forward PTf

Primers

Reverse

Probes

Tag

TGYAAATATCCWGATTATWTIIAAATG 600nM
TGTAGCCAGTATGGYTTATTGAA

600nM

PTrGr2

TGKAGCCAATAAGGTTTATTAAA

600nM

PTrGr3

TGIAICCAATAIGG(CT)TTATTGAA

600nM

PTrGr4

TGTAICCAATATGGtTTATTAAA

600nM

PanGTr
PTp18

TGIAICCARTAIGGYTTATTRAA

600nM

ACTGTGCCTCAATCC
TC+TAA+CTC+TGGC+AA+TAC+TGC

150nM FAM
50nM

YakYel

PTp59

TACTGACATACGTGCC

PTp39

CA+CA+GATAT+ACG+TG+CAA+ACC

PTp51

AGTGGTAATGGCCGTGAC

100nM FAM

PTp56

CAATACCTGCAGAGTTATA

50nM

PTp66

TTGGAAGGGTGGCAAT

PTp16

ATTTGCAGTAGACCCAGAG

150nM FAM

GTGAAACCCCTGGCAGT

150nM HEX

Group 3 PTp45

Group 4

Conc.

PTrGr1

Group 1 PTp52

Group 2

Sequence (5’- 3’)

100nM TexRed
50nM

YakYel

ROX

100nM TAMIN

PTp58

TCCGGTAATACTGCAG

50nM

TexRed

PTp31

TCCGGTTCAACAGCTAC

50nM

FAM

PTp33

TG+CCTCTATT+CAAAG+CAGTGC

50nM

YakYel

PTp35

GTACCACTGGCACATTG

PTp6

TAGTGGAAATCGCACGTCT

100nM ROX
50nM

TAMIN
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Patients and Samples
Patients at high risk for HPV infection were recruited from the HIV clinic at the
Edward Hines, Jr. VA. Inclusion and exclusion criteria are listed in Table 6. The
samples collected included blood for serum, plasma, and peripheral blood mononuclear
cells (PBMCs) as well as anal swabs for HPV detection and clinical histopathological
analysis collected at the time of enrollment and approximately every six months at the
time of clinical visits.
Table 6. HPV Study Subject Recruitment Criteria
Inclusion Criteria

Exclusion Criteria

1. Males/females 18 – 89 yrs. of age. 1. Heterosexual men OR women without CIN
2. MSM or female with l intraepithelial 2. Prior history of anal cancer or cervical
neoplasia of any grade
cancer
3. Patient provides written informed 3. Prior treatment for high grade squamous
consent.
intraepithelial lesion (HSIL)
4. Immunomodulatory therapy, such as
antibodies, calcineurin inhibitors, and
antimetabolite drugs.

PBMC Processing
Blood for plasma and PBMCs was collected using a BD vacutainer mononuclear
Cell Preparation Tube (CPT). After spinning according to the manufacturer instructions,
the plasma was transferred to a 15mL conical and the banded PBMCs located above
the gel divide were transferred to separate a 15mL conical (Fig.12).The PBMCs were
washed 2 times in 10mL of 1X PBS before the cell pellet was resuspended in
autologous freezing media consisting of 90% plasma from the respective sample and
10% DMSO. The remaining plasma as well as serum obtained using a BD Vacutainer
Serum Separation Tube (SST) were aliquoted into 2ml tubes.
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Figure 12 . Layering of Materials in the BD Vacutainer CPT Tube

Pap Smear Processing
The Anal pap smear swabs were placed in PreservCyt, a methanol based
buffered preservative solution. The fixative containing the loose cells was transferred
into 15ml conical tubes and centrifuged at 1500rpm for 15 minutes to pellet the cells.
The cells were then washed once in 1X PBS and resuspended in approximately 1-2 mL
for transfer into multiple 1.7ml eppendorfs. Cells were pelleted in the eppendorfs,
supernatant removed, and cell pellets were frozen at -80oC for future analysis (e.g.
HPV genotyping, HPV quantification, viral and cellular gene and protein expression).
DNA Extraction
DNA was isolated from the pap smear cells using the KingFisher CORE DNA
isolation kit (company !!! cat # A32702) on the King Fisher Flex Magnetic Particle
Processor (Thermo Scientific) according to manufacturer instructions. The samples
were eluted in nuclease free water and stored at -80oC.

CHAPTER THREE
RESULTS
Introduction
In addition to HPV infection being one of the most common sexually transmitted
diseases in the US, there are significant limitations in the clinical detection of HPV. First,
the available tests are only FDA approved for women, meaning that men are often not
tested. Second, out of the 150 different HPV genotypes that exist, most the current
clinical tests only specifically identify two of these genotypes, HPV16 and 18, with the
Roche COBAS 4800 HPV test detecting the other 12 known high oncogenic-risk
genotypes as “other”. This poses a problem for diagnosis and research. As a result, this
project was aimed at establishing HPV genotype-specific TaqMan RTqPCR assays for
the majority of the known oncogenic HPV genotypes, and then using those assays to
perform HPV genotype analysis on clinical samples in order to determine the specific
HPV genotype that exists in each sample, assess prevalence of these genotypes, and
ultimately determine oncogenic risk of these genotypes.
Establishment of HPV Genotype-Specific TaqMan Assays
To enable specific detection of more HPV genotypes, we sought to establish
genotype-specific assays for 13 of the known high oncogenic risk HPV genotypes (i.e.
HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66) and one prevalent low
oncogenic risk HPV genotypes (i.e. HPV6B). Different HPV genotypes can have up to
98% similarity in sequence and so RTqPCR primers and probes must not only be
28
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validated for their ability to quantitatively detect the targeted genotype, but also be
tested to ensure they are specific for only the targeted genotype. To accomplished this,
we utilized genotype-specific TaqMan probes (Table 5). To test the linearity and
sensitivity of each individual assay, we created a 10-fold serial dilution with each of the
HPV genotype plasmids to use as standard curves. When 2uL of these dilutions were
added to the qPCR reactions, they consisted of 4 x 107 to 4 x 100 copies of the HPV
genome per reaction. Water was included as a negative control and was undetermined
in all except the HPV45 assay, where the average water CT was 41.64. The HPV16
assay quantitatively detected the HPV16 genome down to 4 copies with a slope of 3.25
and an R2 of 0.9979 (Fig. 13, Panel A). The HPV18 assay quantitatively detected
HPV18 genome copies down to 4 copies with a slope of 3.32 and an R2 of 0.9984 (Fig.
13, Panel B). The HPV31 assay quantitatively detected HPV31 genome copies down to
4 copies with a slope of 3.43 and an R2 of 0.9982 (Fig. 13, Panel C).The HPV33 assay
quantitatively detected HPV33 genome copies down to 4 copies with a slope of 3.25
and an R2 of 0.9971 (Fig. 13, Panel D). The HPV35, was not as sensitive and only
quantitatively detected HPV35 genome copies down to 40 copies with a slope of 3.95
and an R2 of 0.9896 (Fig. 13, Panel E). In this assay, the 4 copy standard curve was
undetermined indicating the lower limit of detection (LLOD) is somewhere between 4
and 40. The HPV39 assay quantitatively detected HPV39 genome copies down to 40
copies with a slope of 3.66 and an R2 of 0.9984 (Fig. 13, Panel F). Again, the 4 copy
standard curve was undetermined indicating the LLOD is somewhere between 4 and
40. The HPV45 assay quantitatively detected HPV45 genome copies down to 4 copies
with a slope of 3.21 and an R2 of 0.9928 (Fig. 13, Panel G). The HPV51 assay
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quantitatively detected HPV51 genome copies down to 4 copies with a slope of 3.49
and an R2 of 0.9988 (Fig. 13, Panel H). The HPV52 assay quantitatively detected
HPV52 genome copies down to 4 copies with a slope of 3.38 and an R2 of 0.9985 (Fig.
13, Panel I). The HPV56 assay quantitatively detected HPV56 genome copies down to
4 copies with a slope of 3.62 and an R2 of 0.9939 (Fig. 13, Panel J). The HPV58 assay
quantitatively detected HPV58 genome copies down to 4 copies with a slope of 3.32
and an R2 of 0.9959 (Fig. 13, Panel K). The HPV59 assay quantitatively detected
HPV59 genome copies down to 4 copies with a slope of 3.41 and an R2 of 0.9917 (Fig.
13, Panel L). The HPV66 assay quantitatively detected HPV66 genome copies down to
40 copies with a slope of 3.71 and an R2 of 0.9986 (Fig. 13, Panel M). In this assay, the
4 copy standard curve was undetermined indicating the lower limit of detection (LLOD)
is somewhere between 4 and 40. Finally, the HPV6B assay quantitatively detected
HPV6B genome copies down to 4 copies with a slope of 3.54 and an R2 of 0.9993 (Fig.
13, Panel N).
To verify that each assay only recognizes the specific HPV genotype for which
the assay was designed, we included the 108 standard curve sample of all the other
HPV genotypes (i.e. 4 x 107 copies) in each assay to assess cross-detection between
the assays. In all cases, we judged the assays to be specific. In all but two cases, all the
other genotypes tested were not detected at all giving an “undetermined” result (data
not shown). In two cases, CT values were obtained, i.e. the HPV18 assay gave CTs for
HPV56 4x107 samples and the HPV39 assay gave CT values for HPV59 4x107.
However, the CT were very high, and examination of the amplification curve revealed
the CTs were not meaningful, but this might warrant further testing to see if it is
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reproducible or occurs at more physiological template levels.

Figure 13. Performance of our Genotype-Specific HPV TaqMan Assays
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Establishing Pan-Genotypic HPV SYBR Green RTqPCR Assay
Based on the results from the COBAS Roche 4800 HPV test, we were originally
expecting the results from the VA clinical laboratory results to report samples as positive
for HPV16, HPV18 or “other” and planning to run follow-up HPV genotyping analysis on
the positive samples. However, when the results came back from our first set of
patients, we only received results as positive for HPV16 and HPV18/45, indicating that
the VA laboratory was running a less comprehensive test. In the absence of sufficient
clinical data indicating which samples were positive for any of the HPV genotypes
relevant for the study, we sought to establish a pan-genotypic assay as a way to detect
any HPV DNA present in the clinical samples. We used the pan-genotypic forward HPV
primer from the TaqMan assays and designed a pan-genotypic reverse HPV primer to
use in a SYBR-green based assay that has the ability to recognize all 14 HPV
genotypes. We tested the pan-genotypic assay on all 14 of the HPV genotype plasmids
to determine if the assay could recognize each of the HPV genotypes. Specifically, we
ran a 10-fold serial dilution standard curve of each genotype from 4 x 105 to 4 x 100.
Importantly, the pan-genotypic SYBR Green assay was able to recognize all 14 HPV
genotype plasmid DNAs (Fig 14) with minimal background detected in the water control
(equivalent to 0 – 16 copies in individual reactions for an average 0 - 4 copies/per
reaction, except for one case indicated below) . Specifically, the pan-genotypic assay
quantitatively detected HPV16 plasmid copies down to 4 copies with a slope of 3.31 and
an R2 of 0.9988 (Fig. 14, Panel A). The HPV18 genome was also detected down to ~4
copies with a slope of 3.48 and an R2 of 0.9885, however, as can be visualized in the
figure, the 4 copy data point does not fit the slope trend line perfectly and so the
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detection limit is technically perhaps slightly higher than 4 copies (Fig. 14, Panel B).
The HPV31 genome copies were detected down to 4 copies with a slope of 3.65 and an
R2 of 0.9967 (Fig. 14, Panel C).The HPV33 genome copies were detected down to 4
copies with a slope of 3.25 and an R2 of 0.9978 (Fig. 14, Panel D). The HPV35 genome
copies were detected down to almost 4 copies with a slope of 3.37 and an R2 of 0.9821
(Fig. 14, Panel E). The HPV39 genome copies were detected down to 4 copies with a
slope of 3.70 and an R2 of 0.9921 (Fig. 14, Panel F). The HPV45 genome copies were
detected down to almost 4 copies with a slope of 4.15 and an R2 of 0.9957 (Fig. 14,
Panel G). The HPV51 genome copies were detected down to almost 4 copies with a
slope of 3.54 and an R2 of 0.9918 (Fig. 14, Panel H). The HPV52 genome copies were
detected down to almost 4 copies with a slope of 4.20 and an R2 of 0.9869 (Fig. 14,
Panel I). The HPV56 assay was not quite as sensitive, because there was slightly
higher background with the water controls (i.e. 3 water controls were undetermined but
one gave a CT corresponding to 42 copies), hence the HPV56 assay detected the viral
genome down to ~40 copies with a slope of 3.93 and an R2 of 0.9946 (Fig. 14, Panel
J). In this assay, the 4 copy standard curve was undetermined indicating the lower limit
of detection (LLOD) is somewhere between 4 and 40. The HPV58 genome copies were
detected down to 4 copies with a slope of 4.09 and an R2 of 0.9964 (Fig. 14, Panel K).
The HPV59 genome copies were detected down to ~4 copies with a slope of 3.73 and
an R2 of 0.995 (Fig. 14, Panel L). The HPV66 genome copies were detected down to
~4 copies with a slope of 3.65 and an R2 of 0.9955 (Fig. 14, Panel M). Finally, the

34
HPV6B genome copies were detected down to almost 4 copies with a slope of 4.35 and
an R2 of 0.993 (Fig. 14, Panel N).

Figure 14. Performance of the SYBR Green Pan-Genotypic Assay
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Determining if our RTqPCR Assays Accurately Detect HPV in the Context of
Clinical Samples
While all of our assays proved robust using ideal samples created from plasmid
DNA stocks, it is always important to confirm that an assay is able to perform well on
the intended clinical samples. Because we had patient samples that had clinically been
determined to be positive for HPV16 and HPV18/45, we began by testing the HPV16,
HPV18, and HPV45 genotype specific TaqMan assays using one of those clinical
samples. We isolated the cellular DNA from the pap smear of participant HPV-042 and
made a small 2-fold serial dilution of the sample to determine if these three TaqMan
assays could quantitatively detect these HPV genotypes in the sample.

Figure 15. Testing of Genotype Specific TaqMan RTqPCR Using an HPV16+ and
HPV18/45+ Clinical Sample. (A) Standard Curves for HPV16 (blue), HPV18 (green)
and HPV45 (peach) run with each TaqMan assay. (B) Detection of the indicated HPV
genotype in the extracted HPV-042 DNA by the indicated TaqMan assays, a 2-fold
serial dilution of 100ng, 50ng and 25ng of the HPV-042 DNA was assayed.
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Although all three assays robustly detected the genotype specific plasmid DNAs
in the standard curves run in parallel (Fig. 15, top row), none of the three assays
detected any HPV in the clinical samples (Fig 15, bottom row).
To ensure this was not an issue with one sample, we choose additional clinical
samples that had tested positive for HPV16 via clinical testing, HPV-062, HPV-065, and
HPV-072. Additionally, because HPV-042 came up undetermined in our TaqMan
assays, we used this a pseudo-negative control sample and spiked in increasing known
copies of our HPV16 plasmid DNA to determine if we could accurately detect known
copies of HPV copies added. Again, even though the TaqMan HPV16 assay was able
to robustly detect plasmid DNA in the HPV16 standard curve (data not shown), it was
unable to detect HPV16 in at least two additional known positive patient samples (HPV063 and HPV-053)(Fig. 16, blue shaded fields) and it was unable to accurately detect
the level of HPV16 plasmid DNA spiked into the HPV-042 sample (Fig 16, green
shaded fields). Specifically, the spiked DNA was not detected until at least 1000 copies
were added, and then the assay only detected 35 copies (3.5% of the input). At higher
spiked HPV DNA levels the percent detection level improved but was still only between
16 – 20%.
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Figure 16. Testing of HPV16 TaqMan RTqPCR Using HPV16 Positive Clinical
Samples. Blue shaded boxes – different concentrations of HPV+ clinical samples
Green shaded boxes - HPV-042 sample was spiked with increasing copies of HPV16
plasmid DNA from 0 to 10,000 copies.

In parallel, we also tested the ability of our pan-genotypic HPV SYBR Green
assay to detect HPV in the context of clinical samples. To do this, we utilized one HPV
negative clinical sample and individually spiked it with 1000 copies of each of 14 HPV
plasmids before running the pan-genotypic SYBR Green assay. In parallel we spiked
the plasmid DNA into water and then ran the pan-genotypic assay to compare the ability
of the assay to detect the spiked plasmid copies when diluted in water verses added to
50ng of DNA from a clinical sample. (Table 7). While we need to repeat this and ensure
reproducible pipetting, at least initially it appears that 10 of the HPV genotypes are
detected reasonably well by the pan-genotypic SYBR green assay in the context of the
clinical sample. While this assay does not need to be quantitative, it does need to be
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sensitive enough to identify samples positive for the various genotypes. Therefore
additional troubleshooting will be required to ensure all genotypes can be detected in
clinical samples.
Table 7. Results of the Pan-Genotypic SYBR Green Assay on Spiked Clinical
Sample. 1000 copies of the indicated HPV genotype plasmid DNA was spiked into
water and 50ng of DNA extracted from a negative clinical sample. Our pan-genotypic
RTqPCR assay was performed. Quantities were determined based on individual
genotype standard curves. Using the water results as a reference, the percent HPV
detected in the context of the clinical samples is calculated.
HPV
GT
HPV16
HPV18
HPV31
HPV33
HPV35
HPV39
HPV45
HPV51
HPV52
HPV56
HPV58
HPV59
HPV66
HPV6B
No HPV

1000
copies
detected
in water
1482
453
304
368
990
337
1216
711
735
1183
1128
634
1029
644
0

1000 copies
in 50ng
clinical
sample
691
undetermined
394
320
68
undetermined
1431
undetermined
543
665
1089
711
631
911
55

percent detected
in clinical
sample
47%
0%
130%
87%
7%
0%
118%
0%
74%
56%
97%
112%
61%
142%

Interpretation of
clinical context
assay results
~50% sensitivity
FAILED

FAILED
FAILED
FAILED
~50% sensitivity

~50% sensitivity
higher background

Ongoing HPV Clinical Sample Collection
At this point, 111 patients have been enrolled and initial samples have been collected.
Blood samples were processed for plasma, serum and PBMCs. The serum and plasma
samples were aliquoted into 10 eppendorf tubes each and stored at -80°C. The PBMCs
were isolated, washed with PBS, and resuspended in an autologous freezing media.
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They were slow frozen at -80°C. The cells from the anal pap smear samples were
washed with PBS, pelleted, and pellets were stored at -80°C. DNA was isolated from
initial pap samples and was used in the RTqPCR assay validation described.

CHAPTER FOUR
DISCUSSION
Introduction
When this thesis work began, the HPV tests that were available were extremely
limited because they were designed to only specifically detect two of the high-oncogenic
risk HPV genotypes out of the over 150 existing genotypes. As a result, little is known
about the prevalence of the other high-oncogenic risk HPV genotypes or their true
oncogenic risk. Therefore, we planned to establish TaqMan RTqPCR assays to enable
the clinical detection of 13 of the known high oncogenic-risk HPV genotypes and one
known low-oncogenic risk HPV genotype as a means to enhance clinical diagnosis and
research. In Chapter 3, we describe the details of the 14 TaqMan assays that were
developed as well as the development of a pan-genotypic SYBR Green assay. While
these assays exhibited a high degree of sensitivity and specificity in our initial validation
efforts with plasmid DNAs, we encountered sensitivity issues when the assays were
performed on clinical samples.
Discrepancy Between HPV Detection in Plasmid Preparations vs Clinical Samples
In Chapter 3, we showed that our HPV TaqMan and SYBR Green assays are
able to robustly detect all of the tested HPV genotypes when laboratory plasmid
preparations are used to create standard curves; however, we were unable to detect
HPV in clinical samples. Likewise, when we added known copies of the HPV plasmids
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to the DNA extracted from the clinical samples, the sensitivity of the TaqMan assays
was reduced by several logs and the SYBR Green assay sensitivity was likewise
reduced for some of the genotypes. The reduced ability to detect the endogenous HPV
within these samples could be due to the fact that clinical sample is collected in a mild
fixative. Any modification this reagent makes to the sample DNA could be reducing the
efficiency with which it is recognized and subsequently amplified. However, the fact that
the HPV plasmid DNA we spiked into the clinical samples was also not detected well,
suggests that this is at least not the entire issue. That being said, we will test hypothesis
by obtaining some clinical samples in the absence of fixative and subsequently fixing ½
the sample so that we can directly compare assay performance with and without
fixation. The reduced ability to detect exogenously added plasmid DNA could be due to
contaminant(s) in the clinical samples that are inhibiting the RTqPCR reaction. This is
surprising because we are using a bead-based automatic nucleic acid extractor that is
unlikely to carry over contaminants to the final sample, however we can address this
problem by further cleaning up/extracting the clinical samples.
Long-term Goals of this Project and Usefulness of the Samples Collected
While the main focus of this one year cross-sectional thesis project was to
establish and validate genotype-specific RTqPCR assays for the detection of 14 distinct
HPV genotypes (13 oncogenic genotypes and one non-oncogenic genotype), and then
use those assays to screen the initially collected clinical samples to determine the
prevalence of these genotypes and possibly to correlate these genotypes to HPVrelated clinical pathology, the long term objective of this effort is to establish a cohort of
HPV positive patients that can be followed longitudinally to assess not only prevalence
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of the different HPV genotypes, but also correlate HPV genotype with long term cancer
risk/progression. As such, the samples being collected will ultimately be used for many
things in the future. Aside from just isolating HPV DNA for RTqPCR analysis, the cells
from the pap smears can be analyzed for viral and cellular gene and protein expression
in order to determine progression of cancer and potentially identify mechanistic
differences in how the different genotypes lead to transformation, as well as the
presence and location of integration. PBMCs are being banked as they can provide
information regarding patient adaptive immune response against the virus, how this
immune response changes over time, and how it might vary depending HPV genotype.
Serum and plasma samples can be analyzed to give information on the presence of
circulating tumor-DNA, the presence of HPV antibodies and whether their specific/levels
change over time. Importantly, being able to identify biomarkers useful for identifying
HPV infection and/or the progression of disease in easily attainable serum/plasma
samples would also be useful.
Comparing HPV Prevalence in Different Populations
To date, recruitment has been solely from the HIV clinic at the Edward Hines, Jr.
Veteran Affairs Hospital. Once the CoVID19 pandemic restrictions are lifted, enrollment
at the VA will continue. Likewise, samples will be collected from returning patients
approximately every 6 - 12 months (when clinic appointments allow) as part of the
longitudinal analysis. However, this is a rather specific (i.e. older, male-dominated)
population, hence future plans include extending patient recruitment to Loyola
University Medical Center. Recruitment from different clinics at different care centers will
allow for the comparison of results between distinct populations (and distinct anatomical
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sites, i.e. anal vs cervical) to gain an understanding of the different HPV genotypes that
exist in each population.
Strategies for Routine Clinical Testing of Large Numbers of HPV Genotypes
In order to screen for multiple HPV genotypes at the same time in a single
RTqPCR reaction, we attempted to multiplex the TaqMan RTqPCR assays. The
different HPV genotypes were amplified by primer pairs that recognized 3 -4 HPV
genotypes. We then had probes that specifically recognize single HPV genotypes in
each group. By labeling each probe with a different fluorophore, multiplexing should
have been fairly straight forward, without the normal concerns about the multiple primer
pairs competing in the assay. However, unexpectedly we had no success trying to
multiplex these assays.
That being said, even the multiplexing attempted here would be difficult in the
clinical context in which all the HPV genotypes would need to be assays at once, and
ultimately is not necessary. Other types of testing that allow for assaying samples for
many different pathogens at a time have already been developed. For example, the
Biofire FilmArray diagnostic test system runs comprehensive panels of viral, bacterial
and parasitic targets using a simple SYBR Green-like intercalating dye. This is enabled
due to automated aliquoting of the sample into many different assay wells. Likewise, the
Luminex Verigene Enteric Pathogen (EP) test is another diagnostic test system that
uses reverse transcription, PCR and array hybridization to simultaneously detect and
identify nucleic acid gene sequences in a panel of gastrointestinal pathogenic bacteria.
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Notably, a new HPV assay from Becton Dickinson and Company has just received premarket approved less than two weeks ago on July 20, 2020 which is an extension of
their BD Onclarity™ HPV Assay. This extension significantly expands genotype
reporting to include genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66 genotypes.
This is the only FDA-approved assay to individually identify and report these genotype
results (Fig. 17). The test targets E6/E7 region of the HPV viral genome rather than the
L1 region, which can be deleted during HPV DNA integration.

Figure 17. HPV Genotypes Specifically Detected by the new Expanded BD
Onclarity™ HPV Assay. Reproduced from the Becton Dickinson and Company
website.
Conclusion
In conclusion, we have been able to establish 14 HPV genotype specific TaqMan
RTqPCR assays and a pan-genotypic HPV SYBR Green RTqPCR assay which are all
able to quantitatively detect HPV plasmid DNA copies down to 4-40 copies. However,
these assays have not been successfully used to sensitively detect HPV DNA in clinical
samples. The immediate next steps are to troubleshoot these assays to enable the
detection of HPV accurately in clinical samples. Meanwhile, the study team will resume
recruiting more patients for this study and collecting repeat samples from those already

45
enrolled so that they will have a sufficient population to assess once the assays are
ready. Immediately upon successful screening, we hope to determine the overall
prevalence of HPV infection in the patients visiting the infectious disease clinic at the
Edward Hines, Jr. Veteran Affairs Hospital. By comparing the genotypes we detect to
the pathology observed clinically in these patients over time, we also hope to reveal
insight into the oncogenic risk and perhaps individual pathologies exhibited by these
distinct genotypes. Notably, within weeks of this thesis defense, Becton Dickinson and
Company received FDA-approval for a new extended HPV genotype probe-based PCR
test illustrating the recognized importance of accurately diagnosing a broader range of
HPV genotypes. This test is not as extensive of the testing we are planning to do for
research purposes, but it will significantly enhance clinical care and provides an
excellent reference test to help us validate our own in-house testing.
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